Genetic Reevaluation of the Role of F-Box Proteins in Cyclin D1 Degradation

Abstract

D-type cyclins play a pivotal role in G₁-S progression of the cell cycle, and their expression is frequently deregulated in cancer. Cyclin D1 has a half-life of only ∼30 min as a result of its ubiquitylation and proteasomal degradation, with various F-box proteins, including Fbxo4, Fbxw8, Skp2, and Fbxo31, having been found to contribute to its ubiquitylation. We have now generated Fbxo4-deficient mice and found no abnormalities in these animals. Cyclin D1 accumulation was thus not observed in Fbxo4^−/− mouse tissues. The half-life of cyclin D1 in mouse embryonic fibroblasts (MEFs) prepared from Fbxo4^−/−, Fbxw8^−/−, and Fbxo4^−/−; Fbxw8^−/− mice also did not differ from that in wild-type MEFs. Additional depletion of Skp2 and Fbxo31 in Fbxo4^−/−; Fbxw8^−/− MEFs by RNA interference did not affect cyclin D1 stability. Although Fbxo31 depletion in MEFs increased cyclin D1 abundance, this effect appeared attributable to upregulation of cyclin D1 mRNA. Furthermore, abrogation of the function of the Skp1–Cul1–F-box protein (SCF) complex or the anaphase-promoting complex/cyclosome (APC/C) complexes did not alter the half-life of cyclin D1, whereas cyclin D1 degradation was dependent largely on proteasome activity. Our genetic analyses thus do not support a role for any of the four F-box proteins examined in cyclin D1 degradation during normal cell cycle progression. They suggest the existence of other ubiquitin ligases that target cyclin D1 for proteolysis.

View publisher note:

Articles of Significant Interest Selected from This Issue by the Editors

ACKNOWLEDGMENTS

This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Global Center of Excellence Program of the Japanese government.

We thank N. Ishida for technical advice, A. Hatano, S. Kotoshiba, and other laboratory members for technical assistance, and A. Ohta for help in preparation of the manuscript.

We declare no conflicts of interest.